Loading...
OTCMCNTGF
Market cap3mUSD
Dec 23, Last price  
0.12USD
1D
-9.10%
1Q
-38.90%
IPO
-99.06%
Name

Centogene NV

Chart & Performance

D1W1MN
OTCM:CNTGF chart
P/E
P/S
0.07
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
7.23%
Rev. gr., 5y
3.27%
Revenues
48m
+0.14%
27,669,00031,689,00040,478,00048,780,000128,381,000189,923,00047,473,00047,541,111
Net income
-35m
L-10.08%
-5,359,000-5,476,000-11,338,000-20,855,000-21,378,000-46,852,000-38,703,000-34,803,667
CFO
-37m
L+39.54%
1,390,000-4,336,000-4,577,000-7,775,0008,462,000-21,739,000-26,488,000-36,962,489

Profile

Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
IPO date
Nov 07, 2019
Employees
444
Domiciled in
DE
Incorporated in
NL

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
47,541
0.14%
47,473
-75.00%
189,923
47.94%
Cost of revenue
87,835
84,330
235,712
Unusual Expense (Income)
NOPBT
(40,294)
(36,857)
(45,789)
NOPBT Margin
Operating Taxes
281
107
(24)
Tax Rate
NOPAT
(40,575)
(36,964)
(45,765)
Net income
(34,804)
-10.08%
(38,703)
-17.39%
(46,852)
119.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
12,140
BB yield
-48.69%
Debt
Debt current
28,060
6,946
7,224
Long-term debt
64,688
68,612
34,585
Deferred revenue
5,701
6,687
8,028
Other long-term liabilities
6,792
838
Net debt
70,048
43,041
28,429
Cash flow
Cash from operating activities
(36,962)
(26,488)
(21,739)
CAPEX
(2,232)
(2,094)
(5,702)
Cash from investing activities
2,230
(733)
(5,360)
Cash from financing activities
18,641
46,317
(3,203)
FCF
(41,562)
(36,846)
(35,493)
Balance
Cash
19,115
32,008
13,380
Long term investments
3,586
509
Excess cash
20,324
30,143
3,884
Stockholders' equity
(173,733)
7,411
27,503
Invested Capital
235,528
67,558
54,281
ROIC
ROCE
EV
Common stock shares outstanding
28,163
26,811
22,437
Price
1.20
29.03%
0.93
-82.21%
5.23
-51.50%
Market cap
33,795
35.54%
24,935
-78.74%
117,309
-47.96%
EV
103,843
67,976
145,931
EBITDA
(32,840)
(26,479)
(24,498)
EV/EBITDA
Interest
8,201
3,571
851
Interest/NOPBT